BrdU(Proliferation Marker) Antibody (YA6399)

Cat. No.: HY-P86707: Data Sheet User Guide for Antibodies
FAQs
Technical Support

BrdU(Proliferation Marker) Antibody (YA6399) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to BrdU(Proliferation Marker).

For research use only. We do not sell to patients.

Size	Stock	Quantity
20 μL	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 μL	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 μL	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
250 μL	Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

BrdU(Proliferation Marker) Antibody (YA6399) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to BrdU(Proliferation Marker).

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 0.3071 kDa

Species Reactivity

Species independent

SwissProt ID

Gene ID

Immunogen

KLH conjugated Brdu

Application &
Dilution Ratio

Application	Dilution Ratio
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:50-200

Purity	affinity purified.	Conjugation	Non-conjugated
Modification	Unmodified	Isotype	IgG

Appearance

Liquid

Formulation

Supplied in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Bromodeoxyuridine (BrdU) is the most commonly used thymidine analog, which is incorporated into DNA during the S-phase of the cell cycle when DNA is single-stranded, allowing BrdU to bind to the thymidine base pair adenosine; since this only occurs during a fraction of the cell cycle, BrdU labels only a fraction of mitotic cells. Dissolved in saline and injected intraperitoneally, it crosses the blood-brain barrier and can label mitotic cells in the S-phase for up to 2 hours after injection; once incorporated into cells in the adult brain, BrdU remains through several cell divisions without substantial dilution, unlike in the postnatal brain where rapid neuronal division leads to significant dilution in a relatively short time. After euthanasia, brain tissue is fixed with paraformaldehyde, sectioned, and BrdU-containing cells are visualized via standard immunohistochemical techniques using antibodies specific to BrdU—antibody complexes react with peroxidase to give a brown color, or fluorescent secondary antibodies are used (fluorescent techniques allow labeling multiple antigens in a single cell). In neuroscience, BrdU is used to label proliferating cells, contributing to the formation of glia and neurons at specific central nervous system sites; in spinal cord transection experiments, labeled cells are found in lesion-bridging tissue, and in adult neurogenesis studies, it is often combined with glial or neuronal specific antibodies, though it does not determine cell fate alone. Its use is affected by protocol differences like dosage, administration time, animal age, and survival time, with other thymidine analogs (e.g., iododeoxyuridine, chlorodeoxyuridine) and retroviral vectors also used for labeling new cells.

Synonyms

Bromodeoxyuridine; Bromodeoxyuridine; 5-Bromo-2′-deoxyuridine; 5-BrdU; Proliferation Marker; 5-Bromo-2-deoxyUridine.

Documentation

User Guide for Antibodies (1077 KB)